Literature DB >> 29753851

Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment.

Yung-Sung Lee1, Lai-Chu See2, Shu-Hao Chang3, Nan-Kai Wang4, Yih-Shiou Hwang4, Chi-Chun Lai4, Kuan-Jen Chen4, Wei-Chi Wu5.   

Abstract

PURPOSE: To investigate the macular structures, optical components, and visual acuity in preschool-aged children with a history of type I retinopathy of prematurity who underwent either intravitreal bevacizumab (IVB), laser, or a combination of treatments.
DESIGN: Comparative interventional case series.
METHODS: Setting: A referred medical center in Taiwan. STUDY POPULATION: Eighty eyes from 42 patients (33 IVB-treated eyes from 17 children, 24 laser-treated eyes from 13 children, and 23 laser + IVB-treated eyes from 12 children). OBSERVATION PROCEDURE: Spectral-domain optical coherence tomography. MAIN OUTCOME MEASURES: The retinal thickness in the foveal area and the associated morphologic changes in foveal depression.
RESULTS: Compared with the laser-treated and laser + IVB-treated eyes, the IVB-treated eyes had less myopia and deeper anterior chamber depths but presented similar axial lengths and corneal curvatures (P = .001, P = .002, P = .95, and P = .16, respectively). The IVB-treated eyes had significantly thinner foveal, parafoveal, and perifoveal retinal thicknesses (P < .01 for all) and a higher incidence of foveal depression than the laser- or laser + IVB-treated eyes. The macular and subfoveal choroidal thicknesses did not differ among the groups (P = .21 and P = .63, respectively). Moreover, compared with the eyes treated with laser or laser + IVB, the IVB-treated eyes had better uncorrected visual acuity, although a significant difference was not observed in best-corrected visual acuity (P = .008 and P = .29, respectively).
CONCLUSIONS: Compared with laser therapy, IVB-treated eyes were associated with deeper anterior chamber depths and thinner foveal, parafoveal, and perifoveal thicknesses. Moreover, these IVB-treated eyes had fewer refractive errors and better uncorrected visual acuity.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29753851     DOI: 10.1016/j.ajo.2018.05.002

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

Review 1.  [Epidemiology and anatomy of myopia].

Authors:  Jost B Jonas; Songhomitra Panda-Jonas
Journal:  Ophthalmologe       Date:  2019-06       Impact factor: 1.059

2.  Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study.

Authors:  Yu-Bai Chou; An-Guor Wang; Hsin-Yu Yang; Kuan-Jung Chen; Chang-Sue Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-22       Impact factor: 3.117

Review 3.  Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.

Authors:  Georgios N Tsiropoulos; Aikaterini K Seliniotaki; Anna-Bettina Haidich; Nikolaos Ziakas; Asimina Mataftsi
Journal:  Int Ophthalmol       Date:  2022-10-10       Impact factor: 2.029

4.  Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.

Authors:  Emily Wiecek; James D Akula; Deborah K Vanderveen; Iason S Mantagos; Carolyn Wu; Amber-Lee Curran; Hanna De Bruyn; Bridget Peterson; Anne B Fulton
Journal:  Am J Ophthalmol       Date:  2022-03-31       Impact factor: 5.488

5.  Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.

Authors:  Qing-Qing Tan; Stephen P Christiansen; Jingyun Wang
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240

6.  Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity.

Authors:  Jinfeng Zhao; Zhenquan Wu; Waiching Lam; Mingmin Yang; Lu Chen; Lei Zheng; Fuyan Zhang; Jian Zeng; Jiantao Wang; Guoming Zhang
Journal:  Br J Ophthalmol       Date:  2020-02-12       Impact factor: 4.638

7.  Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis.

Authors:  Qihang Kong; Wai-Kit Ming; Xue-Song Mi
Journal:  BMJ Open       Date:  2021-02-10       Impact factor: 2.692

8.  Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity.

Authors:  Michael Simmons; Jingyun Wang; Joel N Leffler; Shanshan Li; Sarah E Morale; Angie de la Cruz; Eileen E Birch
Journal:  Transl Vis Sci Technol       Date:  2021-04-01       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.